show
model
antigen
ovalbumin
ova
chemic
conjug
exterior
small
heat
shock
protein
shsp
cage
structur
similar
viruslik
particl
vlp
ovashsp
conjug
effici
depend
upon
stoichiometri
length
small
molecul
linker
util
attach
posit
shsp
cage
conjug
ovashsp
deliv
intranas
mice
result
immun
respons
ova
acceler
intensifi
ovaspecif
respons
appar
within
day
singl
immun
dose
illustr
util
vaccin
develop
anim
pretreat
dispar
vlp
nonrepl
bacteriophag
capsid
ovashsp
conjug
immun
ovaspecif
respons
appar
alreadi
day
singl
immun
dose
conjug
mice
addit
mice
pretreat
produc
high
titer
mucos
iga
isotypeswitch
ovaspecif
serum
igg
similarli
shsp
pretreat
enhanc
accumul
lung
germin
center
b
cell
follicular
helper
cell
increas
polymer
ig
receptor
express
prime
lung
subsequ
igg
iga
respons
influenza
viru
challeng
thu
shsp
nanoparticl
elicit
quick
intens
antibodi
respons
acceler
respons
could
similarli
induc
antigen
chemic
conjug
shsp
pretreat
mice
acceler
onset
antibodi
respons
ovashsp
demonstr
util
conjug
antigen
vlp
pre
possibl
postexposur
prophylaxi
lung
without
need
adjuv
respiratori
infect
one
promin
afflict
individu
age
immun
status
signifi
signific
global
health
concern
unfortun
current
unabl
provid
vaccin
mani
clinic
relev
lower
respiratori
tract
pathogen
abl
fulli
predict
ident
futur
outbreak
global
vulner
clearli
illustr
sever
epidem
recent
memori
includ
newli
emerg
coronaviru
sarscov
outbreak
variou
influenza
strain
reassort
bird
flu
bioterror
event
involv
pathogen
aerosol
thu
urgent
crucial
need
develop
broadspectrum
rapidli
act
vaccin
strategi
unlik
mucos
site
bodi
protect
immunolog
shape
commens
microbi
commun
lung
less
steril
therefor
lung
reli
intric
network
sentinel
dendrit
cell
antimicrobi
secret
resid
macrophag
defens
importantli
immun
respons
lung
must
tightli
regul
promot
immun
avoid
tissu
damag
associ
either
pathogen
host
respons
pulmonari
immun
respons
quit
uniqu
suggest
other
individu
histori
specif
pathogen
exposur
lung
may
contribut
shape
appropri
ensu
immun
respons
subsequ
challeng
elsewher
demonstr
viruslik
particl
vlp
unrel
antigen
subsequ
challeng
similarli
impact
lung
microenviron
without
associ
patholog
therebi
shape
futur
immun
respons
mani
group
previous
suggest
lung
may
provid
import
rout
deliveri
mucos
vaccin
howev
potenti
util
local
mucos
vaccin
strategi
lower
respiratori
tract
histor
overlook
approach
elicit
tissuespecif
immun
respons
begin
develop
fdaapprov
tribut
realiz
strategi
highli
effect
flumist
vaccin
deliv
intranas
provid
better
comprehens
local
immun
inject
version
addit
applic
nanomateri
biomedicin
one
excit
potenti
revolutionari
applic
nanotechnolog
describ
mechan
enhanc
primari
local
immun
respons
antigen
without
necess
specif
antigen
prime
achiev
result
intranas
deliv
empti
viruslik
particl
vlp
act
modul
lung
microenviron
har
focu
immun
respons
recent
explor
util
nanoparticl
viruslik
particl
virus
mammalian
cell
tropism
shown
platform
natur
immunostimulatori
like
util
evolutionarili
conserv
cell
surfac
receptor
therebi
safe
engag
immun
signal
pathway
without
replic
furthermor
mani
strategi
current
market
undergo
clinic
trial
alreadi
broad
global
impact
safe
prevent
diseas
importantli
viruslik
particl
produc
larg
quantiti
provid
stabl
product
often
amen
lyophil
freezedri
fiscal
econom
featur
especi
import
less
industri
nation
follow
studi
util
two
empti
nonpathogen
viruslik
particl
small
heat
shock
protein
cage
nanoparticl
shsp
phagederiv
viruslik
particl
immunomodulatori
antigen
nonspecif
preprim
scenario
platform
deliveri
specif
antigen
lung
small
heat
shock
protein
shsp
methanocaldococcu
jannaschii
hyperthermophil
archaeon
compris
repeat
subunit
subunit
selfassembl
produc
empti
cagelik
structur
compar
viru
capsid
virtu
high
symmetri
quaternari
structur
previous
shown
shsp
genet
engin
incorpor
cystein
residu
therebi
provid
attach
site
bioconjug
exploit
display
foreign
protein
similarli
describ
strategi
bacteriophag
capsid
infect
salmonella
typhimurium
intact
tail
fiber
present
use
devoid
genet
materi
tail
fiber
therefor
compos
noninfecti
empti
viral
capsid
would
like
note
previous
refer
shsp
nanoparticl
protein
cage
nanoparticl
pcn
howev
find
descript
classifi
shsp
viruslik
particl
given
structur
architectur
immunolog
parallel
particl
describ
literatur
importantli
neither
shsp
target
known
mammalian
patternrecognit
receptor
infect
mammalian
cell
immunomodulatori
potenti
exploit
nonpathogen
virus
still
infanc
other
begun
describ
similar
success
strategi
shsp
herein
use
immunomodulatori
agent
alon
lung
prime
strategi
achiev
heighten
heterolog
immun
distinct
antigen
ova
influenza
viru
case
shsp
vaccin
deliveri
platform
model
antigen
ova
conjug
entireti
exterior
surfac
shsp
cage
immun
strategi
advantag
acceler
intensifi
primari
immun
respons
singl
dose
show
conjug
model
antigen
ova
shsp
elicit
immun
respons
ova
mirror
respons
shsp
shsp
conjug
also
act
adjuv
ova
local
deliveri
shsp
antigen
complex
induc
potent
local
iga
secret
shsp
pretreat
mice
therefor
show
vlp
shsp
use
immunomodulatori
agent
pretreat
lung
andor
carrier
antigen
allow
local
immun
lower
respiratori
tract
pathogen
interest
singl
dose
platform
could
use
preand
postexposur
prophylaxi
product
small
heatshock
protein
cage
nanoparticl
shsp
small
heatshock
protein
shsp
initi
purifi
describ
previous
slight
modif
previous
describ
protocol
supernat
l
cell
cultur
combin
concentr
ml
mwco
amicon
filter
millipor
billerica
prior
size
exclus
chromatographi
superos
column
ge
healthcar
piscataway
nj
purif
larg
amount
shsp
could
accomplish
effici
order
remov
residu
protein
contamin
addit
step
ad
previou
protocol
fraction
contain
shsp
size
exclus
chromatographi
reconcentr
ml
purifi
anion
exchang
sepharos
q
column
ge
healthcar
use
linear
gradient
mm
mm
nacl
mm
hepe
buffer
ph
follow
fraction
contain
shsp
dialyz
overnight
mm
phosphat
mm
nacl
mm
edta
ph
concentr
third
time
ml
resubject
size
exclus
chromatographi
use
superos
column
ge
healthcar
buffer
shsp
variant
protein
tri
phosphin
pierc
rockford
il
ad
final
concentr
mm
amicon
concentr
step
prior
fplc
run
inhibit
disulfid
format
extern
thiol
shsp
shsp
protein
concentr
determin
via
uvvis
spectroscopi
use
extinct
coeffici
mgml
previous
document
larger
aggreg
commerci
avail
ovalbumin
ova
sigmaaldrich
saint
loui
mo
remov
size
exclus
chromatographi
use
superos
column
ge
healthcar
fifti
millimolar
phosphat
mm
nacl
mm
edta
ph
use
elut
buffer
protein
concentr
determin
uvvis
spectroscopi
use
previous
document
extinct
coeffici
mgml
ova
coat
scaffold
protein
express
escherichia
coli
purifi
assembl
vitro
describ
previous
purifi
particl
heat
min
c
remov
scaffold
protein
purifi
sephacryl
column
amersham
piscataway
nj
concentr
mgml
dialyz
extens
mm
phosphat
mm
nacl
ph
concentr
calcul
use
extinct
coeffici
mgml
determin
initi
condit
conjug
matrix
link
condit
test
reaction
carri
mm
phosphat
mm
nacl
mm
edta
ph
ova
l
mgml
label
molar
excess
sm
peg
n
linker
sm
peg
sm
peg
sm
peg
use
stock
solut
mm
linker
dmso
respect
sampl
incub
room
temperatur
min
unconjug
linker
immedi
remov
use
micro
biospin
column
biorad
label
ova
sampl
combin
either
shsp
shsp
cage
use
molar
ratio
protein
combin
vortex
react
h
room
temperatur
overnight
c
final
shsp
concentr
mgml
ova
concentr
mgml
total
volum
l
reaction
reaction
repeat
use
excess
sm
peg
n
linker
sm
peg
sm
peg
sm
peg
stock
solut
mm
label
ova
prior
conjug
lysin
shsp
react
molar
excess
spdp
thermo
scientif
per
shsp
subunit
addit
mm
spdp
dmso
ml
protein
mgml
reaction
stir
min
room
temperatur
label
shsp
purifi
superos
store
c
overnight
reaction
sevenfold
molar
excess
tcep
invitrogen
ad
shspspdp
reduc
spdp
reaction
left
min
room
temperatur
reduc
disulfid
linker
uvvis
spectroscopi
use
monitor
complet
reaction
indic
increas
absorb
nm
correspond
thiopyridon
product
sulfhydryl
function
shsp
react
ova
l
mgml
sampl
label
molar
excess
sm
peg
n
linker
sm
peg
sm
peg
sm
peg
use
protocol
describ
reaction
link
condit
shsp
mutant
combin
ova
contain
final
concentr
mm
tcep
final
shsp
ova
concentr
normal
condit
use
mutant
mgml
mgml
respect
total
volum
l
mm
stock
solut
commerci
label
crosslink
reagent
sm
peg
thermo
scientif
waltham
made
dmso
ova
concentr
mgml
ml
react
molar
excess
linker
ad
dropwis
vigor
stir
solut
reaction
stir
min
room
temperatur
follow
immedi
purif
maleimid
function
ova
unconjug
small
molecul
linker
superos
size
exclus
chromatographi
ge
healthcar
immedi
elut
maleimid
function
ova
concentr
approxim
mgml
use
e
mgml
mwco
microcon
filter
millipor
mix
shsp
mgml
h
room
temperatur
follow
overnight
c
molar
ratio
ova
shsp
use
give
final
concentr
mgml
ova
mgml
shsp
within
link
reaction
control
reaction
contain
ident
concentr
shsp
linkerlabel
ova
alon
run
parallel
free
sulfhydryl
protein
cap
reaction
excess
nethyl
maleimid
pierc
per
shsp
subunit
h
room
temperatur
procedur
repeat
six
time
obtain
suffici
yield
conjug
construct
similar
sampl
reaction
combin
spun
min
g
remov
precipit
dialyz
mm
triethanolamin
usb
corp
santa
clara
ca
ph
sampl
purifi
anion
exchang
chromatographi
monoq
column
amersham
pharmacia
use
linear
gradient
mm
nacl
mm
triethanolamin
ph
fig
fraction
correspond
conjug
sampl
shsp
maleimid
function
ova
combin
base
sdspage
analysi
fraction
shsp
maleimid
function
ova
mix
molar
ratio
obtain
mix
sampl
use
vivo
experi
sampl
extens
dialyz
mm
phosphat
mm
nacl
ph
prior
vivo
experi
admixtur
ova
shsp
compris
equal
microgram
amount
shsp
g
ova
g
sigmaaldrich
conjug
form
suspend
steril
pb
prior
administr
vivo
endotoxin
contamin
protein
prepar
determin
use
limulu
amebocyt
lysat
lal
assay
associ
cape
cod
inc
east
falmouth
determin
shsp
alon
contain
g
lp
per
dose
ovashsp
conjug
contain
ng
lp
per
dose
admixtur
shsp
ova
contain
ng
lp
per
dose
prepar
contain
ng
lp
per
dose
ova
alon
contain
ng
lp
per
dose
second
batch
use
fig
follow
lal
result
lpshigh
contain
g
lp
per
dose
lpslow
contain
ng
per
dose
size
distribut
vlp
determin
use
dynam
light
scatter
brookhaven
particl
size
analyz
bradford
assay
seri
protein
standard
made
use
bsa
sigma
one
hundr
microlit
bradford
reagent
amresco
combin
l
protein
solut
sampl
incub
min
absorb
measur
nm
sampl
also
run
mm
sdspage
reduc
gel
acrylamid
run
gel
acrylamid
stack
gel
alphaeasefc
softwar
alpha
innotech
use
identifi
band
calcul
migrat
distanc
speci
gel
protein
transfer
sdspage
gel
hybond
c
nitrocellulos
membran
h
membran
block
overnight
milk
trisbuff
salin
incub
dilut
rabbit
antiova
polyclon
antibodi
rabbit
antishsp
antibodi
millipor
h
antishsp
antibodi
purifi
rabbit
serum
ammonium
sulfat
precipit
membran
incub
ratio
antirabbit
antibodi
hrpo
conjug
block
solut
min
blot
detect
use
kit
biorad
densitometri
analysi
done
use
alphaeasefc
softwar
alpha
innotech
influenza
viru
produc
trudeau
institut
saranac
lake
ny
briefli
embryon
chicken
egg
infect
h
result
allanto
fluid
recov
store
c
use
balbc
mice
bred
inhous
montana
state
univers
bozeman
mt
week
age
male
femal
mice
enrol
describ
experi
n
per
group
experi
util
intranas
pretreat
g
shsp
deliv
l
volum
mice
lightli
anesthet
inhal
isofluoran
five
pretreat
dose
deliv
either
daili
five
day
space
evenli
cours
week
schedul
produc
equival
result
importantli
extens
explor
potenti
advers
sideeffect
pulmonari
function
due
repeat
shsp
administr
found
none
pretreat
mice
rest
h
challeng
experi
mice
challeng
ovashsp
conjug
ova
shsp
admixtur
ova
alon
shsp
alon
deliv
l
volum
light
anesthesia
ova
concentr
mgml
determin
uvvis
spectroscopi
held
constant
throughout
group
regardless
conjug
subcutan
sc
studi
pretreat
util
instead
one
sc
dose
l
ovashsp
ova
shsp
admixtur
ova
alum
alkso
admixtur
alum
alon
alkso
ova
alon
mgml
inject
antibodi
titer
measur
time
influenza
challeng
studi
plaqu
form
unit
pfu
influenza
viru
deliv
l
experi
determin
impact
residu
lp
mice
similarli
pretreat
lpshigh
lpslow
equal
amount
lp
lpshigh
steril
pyrogenfre
pb
l
mice
rest
subsequ
challeng
g
l
mice
bled
relev
timepoint
serum
separ
whole
blood
centrifug
separ
tube
sarstedt
germani
indic
timepoint
per
experi
mice
euthan
intraperiton
inject
sodium
pentobarbit
mgkg
exsanguin
pedal
respons
could
elicit
mice
lavag
steril
pb
mm
edta
balf
sera
use
determin
antibodi
titer
elisa
experi
lung
tracheobronchi
lymph
node
tbln
addit
collect
either
homogen
wire
mesh
screen
digest
agit
collagenas
worthington
biochem
corpor
lakewood
nj
dnase
sigma
c
h
red
blood
cell
lyse
lung
homogen
use
ack
lysi
buffer
wash
resuspend
fcr
block
clone
stain
flow
cytometri
total
cell
tissu
bal
lung
tbln
count
hemocytomet
case
whole
lung
instil
oct
sakurafinetek
torranc
ca
excis
snap
frozen
liquid
nitrogen
histolog
anim
procedur
preapprov
montana
state
univers
iacuc
experiment
result
confirm
least
two
independ
repetit
similar
design
frozen
block
cut
section
cryostat
leica
microsystem
buffalo
grove
il
result
lung
section
stain
express
polymer
ig
receptor
pigr
biotinyl
goat
antimous
pigr
r
system
minneapoli
mn
follow
invitrogen
carlsbad
ca
control
section
util
determin
stain
specif
imag
acquir
nikon
eclips
microscop
nikon
instrument
melvil
ny
use
nikon
nisel
imag
softwar
antibodi
use
fac
stain
lung
tbln
homogen
includ
fa
streptavidin
bd
pharmingen
san
diego
ca
ebiosci
san
diego
ca
ico
biolegend
san
diego
ca
fac
data
collect
facscanto
bd
fac
analysi
complet
use
flowjo
softwar
treestar
ashland
briefli
forward
side
scatter
plot
gate
lymphocyt
determin
size
granular
lymphocyt
popul
analyz
express
appropri
combin
surfac
antigen
base
neg
stain
control
total
cell
number
calcul
base
total
hemocytomet
cell
count
tissu
serum
balf
antibodi
level
determin
elisa
briefli
highbind
polystyren
plate
corn
corn
ny
coat
incub
antigen
ova
shsp
influenza
viru
membran
prepar
c
h
move
c
overnight
plate
wash
pb
tween
block
nonfat
dri
milk
serum
sampl
dilut
balf
sampl
plate
neat
ml
lavag
duplic
influenzaspecif
elisa
sampl
dilut
dilut
endpoint
titer
elisa
incub
c
h
plate
wash
appropri
hrpconjug
secondari
antibodi
whole
igg
iga
southernbiotech
birmingham
al
ad
incub
addit
h
c
final
plate
wash
develop
use
tmb
substrat
sigmaaldrich
stop
h
po
read
spectramax
plu
plate
reader
molecular
devic
sunnyval
ca
nm
result
ovaspecif
igg
quantifi
use
mous
monoclon
antibodi
ova
abcam
cambridg
statist
signific
determin
oneway
anova
bonferroni
posttest
multipl
comparison
case
unpair
ttest
use
signific
indic
p
p
p
p
graph
symbol
replac
symbol
clariti
comparison
multipl
group
number
symbol
alway
correspond
appropri
pvalu
describ
asterisk
explain
individu
figur
legend
care
optim
condit
conjug
kda
model
antigen
ovalbumin
ova
exterior
surfac
shsp
analysi
reveal
differ
conjug
effici
depend
length
small
molecul
linker
stoichiometri
linker
util
posit
reactiv
group
shsp
architectur
chose
condit
provid
best
yield
conjug
product
avoid
format
protein
aggreg
prepar
conjug
sampl
vivo
experi
see
supplement
materi
prepar
sampl
administr
lung
ova
conjug
exterior
shsp
commerci
avail
heterobifunct
crosslink
reagent
sm
peg
react
lysin
ova
fig
produc
maleimidefunction
ova
fig
immedi
follow
label
ova
sm
peg
unreact
small
molecul
linker
remov
via
size
exclus
chromatographi
maleimidefunction
ova
fig
react
sulfhydryl
group
present
shsp
fig
produc
ovashsp
conjug
fig
subsequ
conjug
unreact
sulfhydryl
shsp
cap
reaction
nethyl
maleimid
inhibit
disulfid
format
sampl
purifi
anion
exchang
chromatographi
effect
separ
free
ova
shsp
ovashsp
conjug
fig
protein
conjug
ovashsp
detect
sdspage
gel
comparison
ovashsp
conjug
sampl
contain
shsp
maleimid
function
ova
admixtur
shsp
fig
ova
conjug
shsp
platform
crosslink
methodolog
util
creat
ovashsp
conjug
shown
ovalbumin
initi
react
commerci
avail
crosslink
reagent
sm
peg
produc
maleimid
function
ova
aii
n
number
linker
attach
function
ova
react
sufhydryl
shsp
cage
ai
yield
ovashsp
conjug
aiii
sampl
use
vivo
administr
analyz
sdspage
b
western
blot
detect
either
shsp
c
ova
lane
panel
correspond
shsp
ova
ii
ovashsp
conjug
iii
unlink
admixtur
iv
shsp
ova
ii
ova
prepar
admixtur
prepar
ratio
ova
per
shsp
cage
ova
concentr
within
sampl
normal
mgml
uvvis
spectroscopi
shsp
oligomer
complex
dissoci
subunit
sdspage
condit
correspond
protein
band
kda
migrat
close
bottom
gel
fig
also
ova
appear
two
band
whole
ova
kda
cleav
ova
kda
fig
previous
describ
protein
band
higher
molecular
weight
kda
fig
repres
polydispers
speci
conjug
ovashsp
later
combin
total
use
ovashsp
conjug
vivo
describ
determin
ova
shsp
present
upper
band
sampl
fig
perform
western
blot
analysi
use
antishsp
fig
antiova
fig
antibodi
reactiv
shsp
ova
antibodi
within
upper
band
conjug
sampl
alon
fig
diii
indic
conjug
ova
shsp
semiquantit
western
blot
fig
suggest
averag
ratio
ova
per
shsp
cage
within
conjug
sampl
total
protein
concentr
conjug
mgml
admix
mgml
shsp
mgml
ova
mgml
sampl
use
vivo
experi
confirm
via
bradford
assay
molecular
weight
band
correspond
ovashsp
conjug
determin
base
upon
migrat
distanc
sdspage
gel
fig
densitometri
analysi
shown
protein
band
correspond
coval
conjug
ova
shsp
subunit
sdspage
gel
identifi
presenc
within
conjug
sampl
fig
absenc
within
shsp
fig
maleimid
function
ova
fig
admixtur
fig
control
detect
band
calcul
molecular
weight
kda
fig
fig
correspond
conjug
singl
shsp
subunit
kda
one
cleav
ova
kda
full
length
ova
kda
respect
upper
band
detect
kda
like
result
variou
form
conjug
ova
shsp
fig
smear
sampl
correspond
molecular
weight
kda
like
repres
conjug
ova
multipl
shsp
subunit
entir
smear
react
antiova
antishsp
antibodi
western
blot
thu
result
conjug
ovashsp
sampl
use
immun
culmin
polydispers
speci
ovashsp
vari
degre
multival
array
architectur
util
size
exclus
chromatographi
dynam
light
scatter
measur
probe
nativ
state
size
distribut
particl
within
sampl
use
immun
ovashsp
conjug
contain
particl
larger
size
admixtur
shsp
ova
size
exclus
chromatographi
indic
distribut
larger
speci
present
within
ovashsp
sampl
fig
dynam
light
scatter
ovashsp
conjug
show
larger
averag
diamet
maleimid
function
ova
shsp
admixtur
rang
averag
diamet
base
intens
measur
sampl
repeat
seven
time
nm
ova
nm
admixtur
nm
shsp
nm
ovashsp
conjug
sampl
fig
first
vivo
studi
determin
potenti
shsp
serv
novel
vaccin
deliveri
platform
abil
facilit
gener
antigenspecif
immun
ova
simultan
determin
pretreat
lung
heterolog
vlp
affect
subsequ
respons
antigen
challeng
balbc
mice
pretreat
either
vehicl
pb
intranas
five
dose
allow
rest
h
mice
challeng
ova
conjug
shsp
ovashsp
ova
shsp
separ
solut
ovashsp
admixtur
ova
alon
shsp
alon
serum
collect
rang
timepoint
postantigen
challeng
kinet
analysi
found
mice
receiv
pretreat
follow
singl
dose
ovashsp
conjug
produc
high
amount
ovaspecif
serum
igg
earli
day
postchalleng
fig
combin
far
outperform
treatment
scenario
rapid
antibodi
product
amount
interestingli
next
highest
antibodi
produc
group
earli
timepoint
mice
also
challeng
singl
dose
ovashsp
conjug
pretreat
vehicl
pb
group
also
produc
significantli
higher
antibodi
titer
remain
combin
although
respons
delay
one
day
compar
mice
receiv
pretreat
conjug
remain
group
howev
achiev
peak
titer
day
postchalleng
equal
earli
respons
delay
day
admixtur
pbsovashsp
admixtur
compar
conjug
group
indic
ovashsp
conjug
immunolog
recogn
differ
admixtur
result
acceler
antibodi
product
also
determin
absolut
concentr
ovaspecif
respons
preand
posttreat
combin
fig
consist
result
mice
pretreat
challeng
ovashsp
conjug
produc
ovaspecif
serum
signific
level
day
quantiti
increas
next
nine
day
second
best
produc
high
quantiti
antibodi
mice
receiv
control
pb
pretreat
challeng
ovashsp
conjug
mice
pretreat
challeng
shsp
ova
admixtur
measur
day
postchalleng
day
postchalleng
amount
ovaspecif
converg
group
shsp
deliv
ova
importantli
two
addit
condit
heighten
acceler
initi
antibodi
productionheterolog
vlp
pretreat
physic
conjug
ova
shsp
discuss
impact
pretreat
subsequ
challeng
demonstr
elicit
acceler
intensifi
immun
respons
weak
antigen
singl
dose
coval
conjug
shsp
previous
demonstr
prime
lung
shsp
elicit
enhanc
immun
respons
subsequ
pathogen
challeng
howev
yet
defin
immun
respons
shsp
therefor
determin
rate
intens
shspspecif
antibodi
respons
pretreat
mice
intranas
vehicl
mice
rest
h
challeng
ovashsp
conjug
ova
shsp
admixtur
ova
alon
shsp
alon
evalu
shspspecif
serum
antibodi
respons
day
postchalleng
fig
found
one
challeng
dose
mice
expos
shsp
gener
strong
shspspecif
respons
peak
earli
day
postchalleng
mice
pretreat
mice
receiv
pretreat
two
day
delay
product
similar
amount
shspspecif
antibodi
howev
day
postchalleng
group
except
control
ovaonli
challeng
mice
gener
similar
level
system
shspspecif
respons
singl
intranas
dose
shsp
antigen
thu
abovedescrib
ovaspecif
respons
fig
mirror
acceler
kinet
shspspecif
respons
indic
shsp
facilit
carrier
effect
result
immun
respons
ova
similar
respons
shsp
onset
antibodi
product
quantiti
produc
sampl
purifi
e
coli
express
system
examin
whether
heighten
antibodi
respons
observ
amplifi
residu
lp
contain
vlp
pretreat
mice
either
lpslow
lpshigh
equival
amount
lp
contain
lpshigh
prepar
steril
pyrogenfre
pb
five
daili
intranas
dose
mice
challeng
shsp
alon
serum
collect
day
evalu
total
antishsp
igg
importantli
found
lpslow
lpshigh
elicit
equal
enhanc
earli
antibodi
respons
heterolog
vlp
challeng
mice
pretreat
lp
fig
addit
pretreat
mice
shsp
pb
challeng
mice
highdos
influenza
viru
importantli
mice
pretreat
shsp
protect
influenzainduc
bodi
weight
loss
regardless
abil
respond
lp
fig
result
indic
observ
heighten
immun
vlp
pretreat
mice
depend
contamin
lp
next
determin
addit
shsp
either
deliv
conjug
admixtur
ova
could
act
adjuv
immun
respons
lung
pretreat
mice
pb
subsequ
challeng
ovashsp
conjug
admixtur
ova
alon
describ
day
postchalleng
determin
level
ovaspecif
serum
igg
subclass
found
conjug
admixtur
prepar
ova
elicit
hightit
serum
antibodi
od
respons
ova
alon
seen
fig
interestingli
howev
ovashsp
conjug
promot
acceler
classswitch
significantli
detect
admixtur
determin
earli
event
isotyp
switch
pretreat
mice
either
shsp
vehicl
challeng
ovashsp
conjug
admixtur
day
serum
collect
ovaspecif
igg
subclass
determin
elisa
found
ovaspecif
total
igg
product
quicker
two
day
mice
pretreat
shsp
challeng
conjug
ovashsp
fig
c
compar
treatment
earli
respons
group
translat
enhanc
product
classswitch
day
postchalleng
fig
e
extent
isotyp
switch
fulli
realiz
group
interestingli
howev
enhanc
classswitch
capac
appear
depend
upon
structur
challeng
antigen
ovashsp
conjug
vs
admixtur
pretreat
shsp
mice
receiv
pb
pretreat
challeng
ovashsp
conjug
gener
significantli
higher
titer
day
postchalleng
challeng
admixtur
shsp
ova
fig
g
littl
produc
timepoint
fig
thu
shsp
act
adjuv
mix
ova
act
carrier
conjug
ova
result
unexpectedli
potent
antibodi
titer
earli
day
singl
immun
mice
found
shsp
strong
mucos
adjuv
next
determin
shsp
would
elicit
similar
respons
deliv
nonmucos
site
subcutan
sc
inject
mice
either
ovashsp
conjug
ova
shsp
admixtur
ova
alon
ova
classic
adjuvantalum
determin
result
serum
antibodi
respons
found
conjug
antigen
shsp
act
strong
adjuv
ova
produc
acceler
ovaspecif
antibodi
respons
earli
day
postchalleng
ovaalum
respons
delay
two
day
compar
fig
ova
shsp
admixtur
elicit
high
titer
antibodi
respons
ova
alum
admixtur
howev
combin
requir
time
produc
similar
result
taken
togeth
shsp
conjug
antigen
act
carrier
elicit
acceler
antibodi
respons
antigen
deliv
sever
immunolog
distinct
site
grow
recognit
import
sitespecif
immun
mucos
surfac
well
tailor
immun
respons
per
tissu
led
us
determin
whether
pretreat
shsp
conjug
shsp
ova
affect
local
iga
product
pretreat
shsp
pb
challeng
either
ovashsp
conjug
admixtur
lung
lavag
fluid
contain
high
level
mucos
iga
igg
mice
pretreat
shsp
fig
b
local
igg
product
enhanc
conjug
shsp
ova
fig
notabl
mani
result
demonstr
admix
ova
shsp
prepar
elicit
enhanc
conjug
admixtur
equal
potent
initi
mucos
iga
respons
fig
shsp
thu
serv
dual
rolefirst
immunomodulatori
agent
pretreat
second
adjuv
specif
antigen
furthermor
found
pretreat
lung
shsp
caus
upregul
polymer
ig
receptor
pigr
lung
epitheli
cell
surfac
prior
antigen
challeng
fig
thu
capac
releas
local
secretori
iga
airway
lumen
enhanc
shsp
pretreat
shsp
pretreat
lung
enhanc
influenzaspecif
antibodi
respons
chang
lung
environ
make
conduc
local
antibodi
respons
previous
shown
shsp
pretreat
mice
subsequ
infect
influenza
acceler
onset
intens
influenzaspecif
igg
respons
similar
shsp
pretreat
enhanc
antibodi
respons
ovashsp
determin
whether
shsp
pretreat
also
affect
fig
conjug
antigen
shsp
result
gener
immun
respons
antigen
shsp
mice
pretreat
vehicl
pb
mice
challeng
either
ovashsp
conjug
ova
shsp
admixtur
shsp
alon
ova
alon
indic
time
serum
collect
shspspecif
measur
elisa
b
mice
pretreat
lpshigh
g
lp
per
dose
lpslow
ng
lp
per
dose
equival
amount
lp
alon
g
per
dose
steril
pyrogenfre
pb
five
dose
mice
challeng
g
shsp
whole
serum
igg
shsp
determin
day
b
statist
day
conjug
group
significantli
higher
level
antibodi
pbsshsp
group
day
conjug
group
significantli
higher
level
antibodi
pbsovashsp
conjug
pbsovashsp
admixtur
group
addit
admixtur
group
significantli
higher
level
antibodi
pbsovashsp
conjug
group
respect
b
day
group
produc
significantli
antibodi
lp
pretreat
group
group
lpshigh
lpslow
p
pb
p
compar
lp
group
kinet
antibodi
class
switch
influenza
infect
ovashsp
mice
pretreat
shsp
control
challeng
pfu
mouseadapt
influenza
viru
determin
correspond
endpointdilut
titer
influenzaspecif
igg
subclass
local
balf
found
expect
due
ova
result
influenzaspecif
balf
igg
enhanc
titer
rate
classswitch
mice
expos
shsp
prior
infect
fig
thu
shsp
pretreat
similarli
affect
antibodi
respons
model
antigen
pathogenassoci
antigen
next
determin
shsp
pretreat
modul
lung
environ
pretreat
mice
shsp
challeng
influenza
found
shsp
pretreat
stimul
format
germin
center
gc
lung
enlarg
gc
b
cell
area
tracheobronchi
lymph
node
tbln
fig
b
tissu
gc
b
cell
preval
least
one
log
shspprime
mice
infect
indic
microenviron
within
lung
local
lymph
node
stimul
adjust
current
antigen
exposur
also
found
follicular
helper
fh
cell
abund
lung
tbln
shspprime
mice
fig
thu
germin
center
reaction
easili
facilit
within
lung
local
lymph
node
shspprime
mice
cours
infect
clear
advantag
gc
organ
establish
observ
gc
b
cell
fh
cell
retain
significantli
higher
number
shspprime
mice
oppos
control
thu
highli
activ
gc
reaction
complet
fh
cell
help
like
facilit
enhanc
antibodi
isotyp
switch
elev
antibodi
product
given
gc
enhanc
also
stain
presenc
plasma
cell
defin
lymphocyt
size
fig
shsp
act
adjuv
lung
mice
pretreat
pb
challeng
ovashsp
conjug
ova
shsp
admixtur
ova
alon
serum
igg
subclass
titer
determin
elisa
day
postchalleng
b
g
mice
pretreat
either
shsp
vehicl
pb
challeng
ovashsp
conjug
ova
shsp
admixtur
day
serum
collect
total
ovaspecif
igg
subclass
determin
elisa
h
mice
pretreat
challeng
sc
ovashsp
conjug
ova
shsp
admixtur
ova
alum
ova
alon
alum
alon
serum
collect
day
ovaspecif
serum
igg
determin
elisa
statist
denot
pbsovashsp
conjug
group
compar
pbsovashsp
admixtur
group
ova
alon
denot
pbsovashsp
admixtur
group
compar
ova
alon
b
c
symbol
use
per
line
indic
signific
group
repres
shspovashsp
conjug
group
signific
compar
pbsovashsp
admixtur
group
pbsovashsp
conjug
group
day
e
day
indic
shspovashsp
conjug
group
signific
pbsovashsp
admixtur
group
also
signific
pbsovashsp
conjug
group
day
h
day
denot
ovashsp
conjug
group
signific
compar
ovaalum
admixtur
day
ovashsp
conjug
group
ovaalum
admixtur
group
signific
compar
remain
group
day
ovashsp
conjug
group
ovaalum
admixtur
group
signific
compar
ova
alon
group
signific
denot
differ
alum
alon
morpholog
loss
without
syndecan
express
upregul
fig
f
interestingli
found
lung
plasma
cell
day
assumedli
secret
antibodi
shsp
markedli
abund
prime
mice
howev
number
cell
present
rapidli
declin
cours
influenza
infect
may
repres
profound
plastic
specif
inhabit
gc
area
lung
describ
other
tbln
plasma
cell
numer
infect
shspprime
mice
howev
remain
elev
compar
control
mice
resolut
infect
point
plasma
cell
number
tbln
group
converg
unlik
lung
howev
similar
trend
follow
group
tbln
surmis
data
shspspecif
plasma
cell
lung
decreas
simultan
influenzaspecif
plasma
cell
increas
therefor
due
like
variabl
rate
influx
efflux
may
exclus
quantifi
rate
increas
influenzaspecif
plasma
cell
due
shsp
prime
remain
puzzl
howev
shspspecif
germin
center
plasma
cell
becom
influenzaor
ovaspecif
acceler
rate
compar
control
mice
given
experiment
data
surmis
other
pulmonari
microenviron
adjust
context
innat
humor
cellular
immun
respons
reaction
menageri
antigen
exposur
encount
uniqu
individu
thu
shsp
pretreat
significantli
enhanc
effici
futur
immun
respons
shown
previous
shsp
pretreat
induc
pulmonari
chang
protect
subsequ
challeng
varieti
pathogen
addit
shsp
pretreat
decreas
tissu
damag
acceler
viral
clearanc
demonstr
shsp
pretreat
conjug
shsp
antigen
interest
provid
enhanc
immun
like
distinct
immunolog
mechan
pretreat
shsp
elicit
organ
gc
lung
tbln
function
acceler
intensifi
onset
antibodi
product
importantli
preprim
lung
shsp
elicit
enhanc
mucos
iga
respons
upregul
epitheli
pigr
respons
depend
upon
physic
conjug
ova
shsp
ova
shsp
admixtur
elicit
iga
product
equal
well
local
balf
igg
product
howev
shsp
pretreat
seem
factor
majorli
respons
enhanc
antibodi
titer
conjug
shsp
ova
also
contribut
final
heterolog
vlp
pretreat
equal
effici
elicit
heighten
immun
demonstr
pretreat
follow
ovashsp
challeng
shsp
pretreat
follow
influenza
challeng
heterolog
immun
extens
describ
context
crossprotect
immun
inappropri
harm
skew
underli
mechan
still
incomplet
defin
demonstr
pretreat
mice
nonpathogen
vlp
stimul
immun
type
prime
result
subsequ
enhanc
respons
ova
furthermor
facilit
pathogen
clearanc
decreas
damag
respons
viral
challeng
fig
ref
addit
pretreat
also
demonstr
util
shsp
novel
vaccin
platform
direct
conjug
antigen
interest
contrast
conjug
antigen
peptid
multival
scaffold
present
conjug
entir
protein
antigen
protein
cage
surfac
vivo
applic
approach
possibl
conjug
antigen
seen
immun
system
part
vlp
elicit
respons
similar
vlp
elicit
previou
work
demonstr
chemic
conjug
effici
larg
unrel
protein
viral
capsid
inhibit
size
protein
increas
condit
chemic
conjug
kda
ova
shsp
cage
optim
protein
observ
attach
posit
shsp
cage
length
chemic
linker
stoichiometri
linker
label
affect
conjug
effici
deliv
ovashsp
conjug
shsp
act
enhanc
ovaspecif
earli
antibodi
product
thu
shsp
act
carrier
caus
ovaspecif
respons
mirror
shspspecif
respons
onset
antibodi
product
quantiti
produc
interestingli
util
shsp
two
scenario
pretreat
vaccin
deliveri
platform
scenario
like
work
distinct
immunostimulatori
mechan
activ
mutual
exclus
fact
synergizea
antibodi
respons
conjug
ovashsp
enhanc
pretreat
either
shsp
yet
defin
exact
cellular
receptor
respons
signal
transduct
initi
immun
respons
vlp
hypothes
repeat
subunit
shsp
allow
abil
crosslink
otherwis
engag
singl
multipl
cellular
receptor
domain
suggest
other
cell
surfac
integrin
antigenpres
cell
like
play
role
recogn
viral
capsid
target
evolutionarili
conserv
domain
therefor
facilit
plastic
deliveri
system
allow
util
shsp
conjug
antigensespeci
complic
preclud
design
manufactur
potent
vaccin
addit
complex
geometri
ovashsp
conjug
may
impact
result
immun
respons
observ
well
demonstr
specif
geometr
display
multival
antigen
significantli
heighten
immun
respons
especi
b
cell
recognit
display
may
even
provid
enough
costimul
break
toler
selfantigen
without
need
adjuv
thu
arrang
ovashsp
conjug
may
explain
enhanc
classswitch
observ
mice
receiv
conjug
form
ovashsp
fig
therefor
demonstr
util
display
poorli
immunogen
antigen
multival
array
conjug
vlp
platform
elicit
enhanc
specif
immun
furthermor
implic
singledos
vaccin
acceler
antibodi
respons
antigen
produc
high
titer
antibodi
within
day
primari
immun
hold
signific
clinic
potenti
regard
new
strategi
employ
postexposur
prophylaxi
repres
arguabl
greater
demand
pretreat
continu
lose
antibiot
option
due
emerg
resist
strain
bacteria
better
predict
futur
viral
outbreak
thu
may
abl
exploit
shsp
conjug
antigen
choic
elicit
earli
iga
respons
importantli
adjuv
current
market
safe
deliv
lung
produc
high
titer
sitespecif
mucos
iga
present
novel
vaccin
platform
amen
easi
manipul
facilit
flexibl
broad
implic
vaccin
strategi
mani
type
pathogen
type
platform
especi
noteworthi
may
util
immunomodulatori
agent
alon
case
pretreat
modifi
current
state
immun
homeostasi
carrier
adjuv
defin
antigen
interest
phenomenon
immun
homeostasi
skew
extens
describ
term
individu
histori
pathogen
allergen
exposur
howev
date
attempt
har
potenti
immun
prime
without
involv
pathogenspecif
epitop
protein
describ
thu
propos
identifi
approach
util
strategi
prime
undefin
broadspectrum
antigen
also
deliv
highli
efficaci
singledos
vaccin
defin
antigen
importantli
addit
shown
rout
deliveri
directli
lung
intranas
instil
result
creation
immun
respons
specif
tailor
tissu
individu
requir
concern
purpos
elicit
immun
respons
lung
justifi
other
indic
elsewher
vlp
power
tissuespecif
immun
har
provid
safe
appropri
respons
context
pathogen
steril
immun
protect
lung
function
furthermor
onset
immun
lung
preexpos
shsp
acceler
indic
pretreat
shsp
impact
futur
unpredict
pathogen
challeng
addit
previous
shown
deposit
vlp
mous
lung
advers
effect
even
attenu
lung
hypersensit
viruslik
particl
nanoparticl
vaccin
strategi
gain
recognit
next
class
safe
effect
platform
notabl
mani
vaccin
expens
produc
requir
refriger
mani
type
vlp
nanoparticl
stabl
easili
preserv
freezedri
creat
opportun
distribut
may
otherwis
preclud
due
cost
logist
therefor
herein
describ
novel
mucos
vaccin
strategi
account
tissuespecif
exploit
natur
immun
provid
acceler
enhanc
antibodi
cellular
immun
respons
primari
antigen
challeng
